G\u00f3mez-Acebo & Pombo has advised Ampersand Capital Partners, a private equity firm based in Boston (USA) specialised in the life sciences and healthcare sector, on an investment in the Spanish company Vivebiotech, which develops viral vectors for rare diseases and cancer.<\/h4>\n\n\n\n
Ampersand’s entry will enable the expansion of the Gipuzkoan biotech company’s lentiviral vector manufacturing capacity and support the execution of its portfolio of pioneering client projects developing innovative cell and gene therapies in vivo and ex vivo.<\/p>\n\n\n\n
The team has been formed by David Gonz\u00e1lez, Diana Linage, Laura Roda and Nicolas Otero, partner, counsel and associates of the Corporate team; Mariana D\u00edaz-Moro and Carla Fandi\u00f1o, partner and associate of the Tax team; Irene Fern\u00e1ndez-Puyol and Marta Rey, partner and associate of the Public team; Lourdes Escassi, Carmen Abad, Laura Calva and Ignacio Luis Campos; counsel and associates of the Labour team; B\u00e1rbara Sainz de Vicu\u00f1a and Diego Iba\u00f1ez; counsel and associate of the IP team; Andrew Ward, partner of the Competition team; Isabel Silva, Joaqu\u00edn Beltr\u00e1n and Patricia Gonz\u00e1lez de Huelbes, associates of the Banking team.<\/p>\n\n\n\n
![\"icon\"](\"https:\/\/ga-pstg.servidortemporal.net\/wp-content\/themes\/ga-p\/assets\/images\/external-icon.svg\"){kind=icon}
<\/div><\/a>\n <\/div>\n\n\n\n<\/p>\n\n<\/div>\n<\/div>\n\n\n
\n <\/span>\n David Gonz\u00e1lez<\/a>\n – Socio<\/span>\n <\/p>\n \n <\/span>\n Diana Linage<\/a>\n – Counsel<\/span>\n <\/p>\n <\/div>\n \n <\/span>\n Mariana D\u00edaz-Moro<\/a>\n – Socia<\/span>\n <\/p>\n \n <\/span>\n Irene Ferna\u0301ndez Puyol<\/a>\n – Socia<\/span>\n <\/p>\n \n <\/span>\n Marta Rey<\/span>\n – Asociada<\/span>\n <\/p>\n \n <\/span>\n Lourdes Escassi<\/a>\n – Counsel<\/span>\n <\/p>\n \n <\/span>\n Carmen Abad<\/span>\n – Asociada<\/span>\n <\/p>\n \n <\/span>\n B\u00e1rbara Sa\u00ednz de Vicun\u0303a<\/a>\n – Counsel<\/span>\n <\/p>\n \n <\/span>\n Diego Ib\u00e1\u00f1ez<\/span>\n – Asociado<\/span>\n <\/p>\n \n <\/span>\n Isabel Silva<\/span>\n – Asociada<\/span>\n <\/p>\n \n <\/span>\n Andrew Ward<\/a>\n – Socio<\/span>\n <\/p>\n \n <\/span>\n Carla Fandi\u00f1o<\/a>\n – Asociada S\u00e9nior<\/span>\n <\/p>\n <\/div>\n \n <\/span>\n Deal<\/span>\n <\/p>\n <\/div>\n \n \n <\/span>\n Corporate and M&A<\/a>\n <\/p>\n \n <\/span>\n Tax<\/a>\n <\/p>\n \n <\/span>\n Public Law and Regulated Sectors<\/a>\n <\/p>\n \n <\/span>\n Employment<\/a>\n <\/p>\n \n <\/span>\n Intellectual Property<\/a>\n <\/p>\n \n <\/span>\n Banking and Finance<\/a>\n <\/p>\n \n <\/span>\n Life Sciences and Healthcare<\/a>\n <\/p>\n <\/div>\n <\/div>\n<\/div>\n\n<\/div>\n<\/div>\n\n<\/div>\n\n <\/div>\n\n<\/div>\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" G\u00f3mez-Acebo & Pombo has advised Ampersand Capital Partners, a private equity firm based in Boston (USA) specialised in the life sciences and healthcare sector, on an investment in the Spanish company Vivebiotech, which develops viral vectors for rare diseases and cancer.<\/p>\n","protected":false},"featured_media":0,"template":"","categoria":[117],"class_list":["post-324801","noticia","type-noticia","status-publish","hentry","categoria-deal-en"],"acf":[],"yoast_head":"\n![\"icon\"](\"https:\/\/ga-pstg.servidortemporal.net\/wp-content\/themes\/ga-p\/assets\/images\/arrow-down-flu-color.svg\"){kind=icon}
<\/div>\n <\/div>\n <\/div>\n \n ![\"icon\"](\"https:\/\/ga-pstg.servidortemporal.net\/wp-content\/themes\/ga-p\/assets\/images\/arrow-left-primary.svg\"){kind=icon}
\n <\/a>\n See next ![\"icon\"](\"https:\/\/ga-pstg.servidortemporal.net\/wp-content\/themes\/ga-p\/assets\/images\/arrow-right-primary.svg\"){kind=icon}
\n <\/a>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n\n<\/div>\n\n <\/div>\n\n<\/div>\n\n\n\n